GlobeNewsWire
07 Jan 2026, 21:05 UTC · 45w ago
Phathom Pharmaceuticals Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
Impact · against what's priced in
Phathom Pharmaceuticals is likely to face short-term share price pressure due to the announced public offering of common stock and warrants. The resulting dilution typically outweighs the positive utility of the capital infusion for general corporate and R&D purposes.
- PHAT−0.20
No priced-in read yet





